Seeking patient care?
The University of Miami Headache Division is committed to advancing the science and care of migraine and other headache disorders through cutting-edge clinical trials, patient-centered research, and interdisciplinary team science.
We actively engage with patients as partners in discovery, offering opportunities to participate in research that can shape the future of headache medicine. Our work is supported by the Clinical and Translational Science Institute (CTSI), providing the infrastructure to move ideas into clinical practice.
In pursuit of transformative progress, we seek to collaborate with foundations, industry sponsors, and federal agencies to accelerate innovation, improve treatments, and reduce the burden of headache disorders on individuals and society.
| Study Name | Study | Status |
|---|---|---|
| C-BEOND/ | The BEOND studies are researching an investigational drug for patients with migraine. There are two studies: one study on chronic migraine and one study in episodic migraine. The goal of these studies is to determine if the investigational drug is safe and effective for people living with migraines. The two studies are focused on assessing the efficacy and safety for an investigational use of Dysport® which is a formulation of Botulinum toxin type A (BoNT-A). Through research it is believed that Dysport® (abobotulinumtoxin A) may work on the release of the chemical messengers causing migraine pain. Dysport® is not approved by health authorities (such as the US Food and Drug Administration (FDA)) for the treatment of migraine. Our researchers now want to assess its potential for this use. | Actively recruiting |
| UNCHAINED/ ID NCT05216263 | Study of Oral Atogepant When Added to OnabotulinumtoxinA (BOTOX) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Chronic Migraine (ATO-BOTOX) | No longer actively recruiting |
| TRIUMPH/ | The TRIUMPH study, initiated by Eli Lilly, is a real-world evidence study focused on evaluating the effectiveness of Emgality (galcanezumab-gnlm) and comparing it to other migraine preventative treatments. It aims to assess long-term outcomes and treatment patterns in patients with migraine, including changes in migraine frequency, quality of life, and treatment satisfaction. | No longer actively recruiting |